Company Description
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines.
The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform.
The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.
All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines.
The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.
The company was founded in 2024 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2024 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Daphne Zohar |
Contact Details
Address: 101 Seaport Blvd., Floor 12 Boston, Massachusetts 02210-2186 United States | |
| Phone | (617) 807-4062 |
| Website | seaporttx.com |
Stock Details
| Ticker Symbol | SPTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2042347 |
| Employer ID | 99-2235719 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Chief Executive Officer and Director |
| Michael C. Chen, Ph.D. | Chief Scientific Officer |
| Lana Gladstein, J.D. | General Counsel |
| Antony Loebel, M.D. | Chief Medical Officer |
| Lauren A. White | Chief Financial Officer |
| Steven M. Paul, M.D. | Director and Board Chair |
| Eric Elenko, Ph.D. | Director |
| James I. Healy, M.D., Ph.D. | Director |
| Robert J. Hombach | Director |
| Robert Nelsen | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2026 | 424B4 | Prospectus |
| Apr 30, 2026 | EFFECT | Notice of Effectiveness |
| Apr 30, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Apr 30, 2026 | CERT | Certification by an exchange approving securities for listing |
| Apr 28, 2026 | 8-A12B | Registration of securities |
| Apr 27, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 27, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |